LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Kodu・Aktsiate loetelu・Boston Scientific Corp.

Boston Scientific Corp.

Suletud

SektorTervishoid

57.61 1.02

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

57.41

Max

57.67

Põhinäitajad
By Trading Economics
Sissetulek	669M 1.3B
Müük	-83M 5.2B
P/E Sektori keskmine	23.398 49.701
Aktsiakasum	0.8
Kasumimarginaal	25.774
Töötajad	59,000
EBITDA	116M 1.1B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+51.66% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	29. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-7.5B 83B
Eelmine avamishind	56.59
Eelmine sulgemishind	57.61

Uudiste sentiment

By Acuity

26%

74%

59 / 345 Pingereas Healthcare

Boston Scientific Corp. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. mai 2026, 11:04 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific Buys 34% Stake in MiRus for $1.5 Billion

22. apr 2026, 11:22 UTC

Tulu

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adjusted EPS View

4. veebr 2026, 16:14 UTC

Tulu

Suurimad hinnamuutused turgudel

Boston Scientific Plunges on Disappointing 1Q Outlook Despite 4Q Earnings Beat

4. veebr 2026, 12:13 UTC

Tulu

Boston Scientific Sees More Growth after Earnings, Sales Rise

6. mai 2026, 20:15 UTC

Tulu

Penumbra Not Be Providing Fincl Guidance Due to Pending Acquisition by Boston Scientific >PEN

6. mai 2026, 20:07 UTC

Tulu

Penumbra 1Q Rev $374.8M >PEN

6. mai 2026, 20:07 UTC

Tulu

Penumbra 1Q EPS 82c >PEN

22. apr 2026, 11:07 UTC

Tulu

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adj EPS View

22. apr 2026, 10:32 UTC

Tulu

Boston Scientific Now Sees 2026 Reported Sales Up 7%-8.5%, Organic Sales Up 6.5%-8% >BSX

22. apr 2026, 10:31 UTC

Tulu

Boston Scientific Sees 2Q Reported Sales Up 5.5%-7.5%, Organic Sales Up 5%-7% >BSX

22. apr 2026, 10:30 UTC

Tulu

Boston Scientific 1Q Organic Sales Up 9.4% >BSX

22. apr 2026, 10:30 UTC

Tulu

Boston Scientific 1Q Adj EPS 80c >BSX

22. apr 2026, 10:30 UTC

Tulu

Boston Scientific 1Q EPS 90c >BSX

22. apr 2026, 10:30 UTC

Tulu

Boston Scientific 1Q Sales $5.2B >BSX

22. apr 2026, 10:30 UTC

Tulu

Boston Scientific Sees 2Q Adj EPS 82c-Adj EPS 84c >BSX

22. apr 2026, 10:30 UTC

Tulu

Boston Scientific Sees FY Adj EPS $3.34-Adj EPS $3.41 >BSX

30. märts 2026, 15:34 UTC

Market Talk

Boston Scientific Faces Some Slowing Growth Trends -- Market Talk

4. veebr 2026, 21:41 UTC

Tulu

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4. veebr 2026, 19:38 UTC

Tulu

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4. veebr 2026, 17:32 UTC

Tulu

These Stocks Are Today's Movers: AMD, AbbVie, Eli Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More -- Barrons.com

4. veebr 2026, 15:30 UTC

Tulu

Boston Scientific Earnings Beat Estimates. It's the Worst Stock in the S&P 500 Today. -- Barrons.com

4. veebr 2026, 15:29 UTC

Tulu

These Stocks Are Today's Movers: AMD, Eli Lilly, AbbVie, Uber, Super Micro, Enphase, Boston Scientific, and More -- Barrons.com

4. veebr 2026, 14:06 UTC

Tulu

Boston Scientific Profit, Sales Rise but Issues Soft Guidance -- Update

4. veebr 2026, 13:58 UTC

Tulu

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4. veebr 2026, 13:12 UTC

Tulu

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4. veebr 2026, 11:32 UTC

Tulu

Boston Scientific Sees 2026 Sales Up 10.5%-11.5%, Organic Sales Up 10%-11% >BSX

4. veebr 2026, 11:31 UTC

Tulu

Boston Scientific Sees 1Q Sales Up 10.5%-12%, Organic Sales Up 8.5%-10% >BSX

4. veebr 2026, 11:30 UTC

Tulu

Boston Scientific 4Q Organic Sales Up 12.7% >BSX

4. veebr 2026, 11:30 UTC

Tulu

Boston Scientific Sees 2026 Adj EPS $3.43-Adj EPS $3.49 >BSX

4. veebr 2026, 11:30 UTC

Tulu

Boston Scientific Sees 1Q Adj EPS 78c-Adj EPS 80c >BSX

Võrdlus sarnastega

Hinnamuutus

Boston Scientific Corp. Prognoos

Hinnasiht

By TipRanks

51.66% tõus

12 kuu keskmine prognoos

Keskmine 87.63 USD 51.66%

Kõrge 118 USD

Madal 68 USD

Põhineb 27 Wall Streeti analüütiku instrumendi Boston Scientific Corp. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

27 ratings

Osta

Hoia

Müü

Põhineb 27 analüütiku instrumendi Boston Scientific Corp. aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

59 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.